CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

• Status: NOT_YET_RECRUITING
• Trial end date: 2027-09-01

Summary

The aim of this study is to evaluate the efficacy and safety of CAR T-cell therapy in combination with glofitamab for the treatment of relapsed/refractory large B-cell lymphoma with high-risk prognostic factors.

• Phase: PHASE2

Details

• Lead Sponsor: Ruijin Hospital
• Treatments: glofitamab; Immunotherapy, Adoptive; obinutuzumab